Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with mortality in a community-based cohort of older Swedish men

Atherosclerosis

Volumn 227, Issue 2, 2013, Pages 408-413

  Helmersson Karlqvist, Johanna ^a   Larsson, Anders ^a   Carlsson, Axel C ^b,c   Venge, Per ^a   Sundström, Johan ^a   Ingelsson, Erik ^b   Lind, Lars ^a   Ärnlöv, Johan ^c,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d DALARNA UNIVERSITY   (Sweden)

Author keywords

Chronic kidney disease; Epidemiology; Inflammation; Mortality; NGAL; Risk factors

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CYSTATIN C; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT DURATION;

ACUTE-PHASE PROTEINS; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LIPOCALINS; MALE; PROTO-ONCOGENE PROTEINS; REGISTRIES; REGRESSION ANALYSIS; RISK FACTORS; SWEDEN; TIME FACTORS;

EID: 84875053911     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.009     Document Type: Article

References (40)

1. Kjeldsen L., Johnsen A.H., Sengelov H., Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993, 268:10425-10432.
2. Xu S.Y., Carlson M., Engström A., Garcia R., Peterson C.G., Venge P. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scand J Clin Lab Invest 1994, 54:365-376.
3. Goetz D.H., Willie S.T., Armen R.S., Bratt T., Borregaard N., Strong R.K. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 2000, 39:1935-1941.
4. Bolignano D., Donato V., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008, 52:595-605.
5. Mishra J., Ma Q., Prada A., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14:2534-2543.
6. Ronco C. N-GAL: diagnosing AKI as soon as possible. Crit Care 2007, 11:173.
7. Urbschat A., Obermuller N., Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011, 16(Suppl. 1):S22-S30.
8. Mårtensson J., Bell M., Oldner A., Xu S., Venge P., Martling C.R. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med 2010, 36:1333-1340.
9. Mitsnefes M.M., Kathman T.S., Mishra J., et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007, 22:101-108.
10. Bolignano D., Lacquaniti A., Coppolino G., Campo S., Arena A., Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 2008, 31:255-258.
11. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:337-344.
12. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res 2009, 32:91-98.
13. Bolignano D., Coppolino G., Lacquaniti A., Buemi M. From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology. Eur J Clin Invest 2010, 40:273-276.
14. Damman K., van Veldhuisen D.J., Navis G., Voors A.A., Hillege H.L. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008, 10:997-1000.
15. Poniatowski B., Malyszko J., Bachorzewska-Gajewska H., Malyszko J.S., Dobrzycki S. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in patients with chronic heart failure and coronary artery disease. Kidney Blood Press Res 2009, 32:77-80.
16. Elneihoum A.M., Falke P., Axelsson L., Lundberg E., Lindgärde F., Ohlsson K. Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischemic cerebrovascular diseases. Stroke 1996, 27:1734-1738.
17. Anwaar I., Gottsater A., Ohlsson K., Mattiasson I., Lindgärde F. Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia. Cerebrovasc Dis 1998, 8:310-317.
18. Falke P., Elneihoum A.M., Ohlsson K. Leukocyte activation: relation to cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis 2000, 10:97-101.
19. Bolignano D., Basile G., Parisi P., Coppolino G., Nicocia G., Buemi M. Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Res 2009, 12:7-14.
20. Maisel A.S., Mueller C., Fitzgerald R., et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011, 13:846-851.
21. Daniels L.B., Barrett-Connor E., Clopton P., Laughlin G.A., Ix J.H., Maisel A.S. Plasma neutrophil gelatinase-associated lipocalin is independently associated with cardiovascular disease and mortality in community-dwelling older adults: the Rancho Bernardo study. J Am Coll Cardiol 2012, 59:1101-1109.
22. Byberg L., Siegbahn A., Berglund L., McKeigue P., Reneland R., Lithell H. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol 1998, 18:258-264.
23. Helmersson J., Vessby B., Larsson A., Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004, 109:1729-1734.
24. Zethelius B., Berglund L., Sundström J., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116.
25. Larsson A., Malm J., Grubb A., Hansson L.O. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004, 64:25-30.
26. Hall W.D. Abnormalities of kidney function as a cause and a consequence of cardiovascular disease. Am J Med Sci 1999, 317:176-182.
27. Ärnlöv J. Diminished renal function and the incidence of heart failure. Curr Cardiol Rev 2009, 5:223-227.
28. Laterza O.F., Price C.P., Scott M.G. Cystatin C: an improved estimator of glomerular filtration rate?. Clin Chem 2002, 48:699-707.
29. Mann J.F., Gerstein H.C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
30. Larsson A., Helmersson J., Hansson L.O., Basu S. Increased serum cystatin C is associated with increased mortality in elderly men. Scand J Clin Lab Invest 2005, 65:301-305.
31. Nerpin E., Ingelsson E., Riserus U., et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant 2011, 26:2820-2827.
32. Bennett M., Dent C.L., Ma Q., et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008, 3:665-673.
33. Haase-Fielitz A., Bellomo R., Devarajan P., et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery - a prospective cohort study. Crit Care Med 2009, 37:553-560.
34. Ding H., He Y., Li K., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 2007, 123:227-234.
35. Haraldsson B., Nyström J., Deen W.M. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 2008, 88:451-487.
36. Comper W.D., Russo L.M. The glomerular filter: an imperfect barrier is required for perfect renal function. Curr Opin Nephrol Hypertens 2009, 18:336-342.
37. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369.
38. Awad A.S., Rouse M., Huang L., et al. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009, 75:689-698.
39. Cai L., Rubin J., Han W., Venge P., Xu S. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010, 5:2229-2235.
40. Xu S.Y., Petersson C.G., Carlson M., Venge P. The development of an assay for human neutrophil lipocalin (HNL) - to be used as a specific marker of neutrophil activity in vivo and vitro. J Immunol Methods 1994, 171:245-252.